NCT06046066 - A Phase 1 Study of NM6603 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions

Cancers

Interventions

DRUG

NM6603

NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.

Trial Locations (4)

44195

RECRUITING

Cleveland Clinic Taussig Cancer Center, Cleveland

48201

RECRUITING

Karmanos Cancer Institute, Detroit

73203

RECRUITING

Tennessee Oncology, PLLC, Nashville

77030

RECRUITING

MD Anderson Cancer Center, Houston